Keyphrases
Treatment Group
100%
Hepatitis C Virus Infection
100%
Phase II Study
100%
Grazoprevir
100%
Elbasvir
100%
Inherited Blood Disorders
100%
Immediate Treatment
83%
Placebo
50%
SVR12
50%
Hemoglobin Level
33%
Thalassemia
33%
Hemophilia
33%
Von Willebrand Disease
33%
United States
16%
Israel
16%
Europe
16%
Australia
16%
Canada
16%
Once-daily
16%
Change in Mean
16%
Ratio Values
16%
Serious Adverse Events
16%
International Normalized Ratio
16%
Hemoglobinopathies
16%
Sickle Cell Anemia
16%
Active Treatment
16%
Tolerability
16%
Direct-acting Antivirals
16%
Sustained Virological Response
16%
Randomized Placebo-controlled Trial
16%
Lost to Follow-up
16%
Hepatitis C Virus RNA
16%
Thailand
16%
Fixed-dose Combination
16%
Group Treatment
16%
Sickle Cell Disease
16%
Inherited Bleeding Disorders
16%
Hepatology
16%
Deferred Treatment
16%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis C
100%
Hematologic Disease
100%
Grazoprevir
100%
Elbasvir
100%
Treatment Group
100%
Placebo
66%
Von Willebrand Disease
33%
Haemophilia A
33%
Adverse Event
16%
Thalassemia
16%
Hemoglobinopathy
16%
Sickle Cell Anemia
16%
Tolerability
16%
Hepatitis C Virus
16%
Virus RNA
16%
Bleeding Disorder
16%
Sickle Cell Beta Thalassemia
16%
Antiviral Drug
16%